Gene Expression Profiling of Breast Cancer

Advances in Surgery

Volumn 42, Issue C, 2008, Pages 249-260

  Bao, Ting ^a   Davidson, Nancy E ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BREAST TUMOR; FEMALE; GENE EXPRESSION PROFILING; GENETICS; HUMAN; PROGNOSIS; REVIEW;

BREAST NEOPLASMS; FEMALE; GENE EXPRESSION PROFILING; HUMANS; PROGNOSIS;

EID: 49849105624     PISSN: 00653411     EISSN: None     Source Type: Book Series    
DOI: 10.1016/j.yasu.2008.03.002     Document Type: Review

References (29)

1. van't Veer L.J., Paik S., and Hayes D.F. Gene expression profiling of breast cancer: a new tumor marker. J Clin Oncol 23 (2005) 1631-1635
2. Lipshutz R.J., Morris D., Chee M., et al. Using oligonucleotide probe arrays to access genetic diversity. Biotechniques 19 (1995) 442-447
3. Schena M., Shalon D., Davis R.W., et al. Quantitative monitoring of gene expression patterns with a complementary DNA microarray. Science 270 (1995) 467-470
4. Quackenbush J. Microarray analysis and tumor classification. N Engl J Med 354 (2006) 2463-2472
5. Cronin M., Pho M., Dutta D., et al. Measurement of gene expression in archival paraffin-embedded tissues: development and performance of a 92-gene reverse transcriptase-polymerase chain reaction assay. Am J Pathol 164 (2004) 35-42
6. Perou C.M., Sorlie T., Eisen M.B., et al. Molecular portraits of human breast tumours. Nature 406 (2000) 747-752
7. Morris S.R., and Carey L.A. Molecular profiling in breast cancer. Rev Endocr Metab Disord 8 (2007) 185-198
8. Sorlie T., Tibshirani R., Parker J., et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A 100 (2003) 8418-8423
9. Sorlie T., Perou C.M., Tibshirani R., et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 98 (2001) 10869-10874
10. van't Veer L.J., Dai H., van de Vijver M.J., et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 415 (2002) 530-536
11. van de Vijver M.J., He Y.D., van't Veer L.J., et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347 (2002) 1999-2009
12. Buyse M., Loi S., van't Veer L., et al. Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J Natl Cancer Inst 98 (2006) 1183-1192
13. Paik S., Shak S., Tang G., et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351 (2004) 2817-2826
14. Goldstein L RP, Gray R, Yoshizawa C, et al. Prognostic utility of the 21-gene assay compared with Adjuvant! in hormone receptor (HR) positive operable breast cancer with 0-3 positive axillary nodes treated with adjuvant chemohormonal therapy (CHT): an analysis of intergroup trial E2197. Abstract #63. San Antonio Breast Cancer Symposium. San Antonio, Texas; 2007.
15. Habel L.A., Shak S., Jacobs M.K., et al. A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients. Breast Cancer Res 8 3 (2006) R25
16. Gianni L., Zambetti M., Clark K., et al. Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer. J Clin Oncol 23 (2005) 7265-7277
17. Paik S., Tang G., Shak S., et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 24 (2006) 3726-3734
18. Foekens J.A., Atkins D., Zhang Y., et al. Multicenter validation of a gene expression-based prognostic signature in lymph node-negative primary breast cancer. J Clin Oncol 24 (2006) 1665-1671
19. Wang Y., Klijn J.G., Zhang Y., et al. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 365 (2005) 671-679
20. Chang H.Y., Sneddon J.B., Alizadeh A.A., et al. Gene expression signature of fibroblast serum response predicts human cancer progression: similarities between tumors and wounds. PLoS Biol 2 (2004) 206-214
21. Ma X.J., Wang Z., Ryan P.D., et al. A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. Cancer Cell 5 (2004) 607-616
22. Fan C., Oh D.S., Wessels L., et al. Concordance among gene-expression-based predictors for breast cancer. N Engl J Med 355 (2006) 560-569
23. Li C.I., Daling J.R., and Malone K.E. Incidence of invasive breast cancer by hormone receptor status from 1992 to 1998. J Clin Oncol 21 (2003) 28-34
24. Carlson R.W., Brown E., Burstein H.J., et al. NCCN Task Force report: adjuvant therapy for breast cancer. J Natl Compr Canc Netw 4 Suppl 1 (2006) S1-S26
25. Fisher B., Jeong J.H., Dignam J., et al. Findings from recent National Surgical Adjuvant Breast and Bowel Project adjuvant studies in stage I breast cancer. J Natl Cancer Inst Monogr 30 (2001) 62-66
26. Sparano J. Design of and rationale for the Trial Assigning Individualized Options for Treatment (TAILORx). In: Govindan R. (Ed). American Society of Clinical Oncology educational book vol. 43 (2007), Greaves, Lisa, Alexandria (VA) 34-39
27. MINDACT Trial Outline. Available at:. http://www.eortc.be/services/unit/mindact/documents/MINDACT_trial_outline.pdf Accessed April 29, 2008
28. Goetz M.P., Rae J.M., Suman V.J., et al. Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol 23 (2005) 9312-9318
29. Stebbing J., Stearns V., and Davidson N.E. Role of CYP2D6 testing in selection of endocrine therapy for breast cancer. Pharmacogenomics 8 (2007) 1-3